LV009 clinical trials
How each study uses LV009 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LV009 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · The First Affiliated Hospital with Nanjing Medical University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test LV009.
- Dec 2026Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesPhase 1 · PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Studies
Open first, then newest update. How each study uses LV009 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood TumorsNot yet recruitingEarly Phase 1The First Affiliated Hospital with Nanjing Medical UniversityNCT07330895Written as Biological: LV009 injectionHow we know
- Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid MalignanciesRecruitingEarly Phase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07312630Written as LV009 Injection InfusionHow we know
- Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid MalignanciesRecruitingPhase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT07284927Written as LV009 InjectionHow we know